Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in combination with either pembrolizumab or cetuximab as a strategy to overcome tumor ...
78% reduction in risk of death and 81% reduction in risk of progression or death in defined pretreatment ranges of serum or tumor CEACAM1 subgroup 61% reduction is risk of death and 72% reduction in ...
Purple Biotech Ltd. announced significant progress in its clinical development pipeline during the AACR Annual Meeting 2025, providing updates on its therapies CM24 and NT219, and progressing toward ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results